Your browser is no longer supported. Please, upgrade your browser.
NVS Novartis AG daily Stock Chart
Novartis AG
Index- P/E27.25 EPS (ttm)2.80 Insider Own9.30% Shs Outstand2.62B Perf Week4.54%
Market Cap199.64B Forward P/E14.65 EPS next Y5.20 Insider Trans0.27% Shs Float2.53B Perf Month2.51%
Income6.71B PEG4.93 EPS next Q1.12 Inst Own10.60% Short Float0.15% Perf Quarter12.83%
Sales49.44B P/S4.04 EPS this Y-2.80% Inst Trans0.04% Short Ratio1.37 Perf Half Y4.60%
Book/sh31.55 P/B2.42 EPS next Y10.89% ROA5.10% Target Price85.25 Perf Year3.29%
Cash/sh2.97 P/C25.67 EPS next 5Y5.53% ROE9.10% 52W Range64.58 - 80.64 Perf YTD8.48%
Dividend2.72 P/FCF94.12 EPS past 5Y-5.80% ROI7.30% 52W High-5.46% Beta0.79
Dividend %3.57% Quick Ratio0.80 Sales past 5Y-3.60% Gross Margin65.10% 52W Low18.06% ATR0.78
Employees118393 Current Ratio1.10 Sales Q/Q-1.50% Oper. Margin16.40% RSI (14)65.20 Volatility0.79% 0.72%
OptionableYes Debt/Eq0.32 EPS Q/Q-8.00% Profit Margin13.60% Rel Volume1.27 Prev Close74.61
ShortableYes LT Debt/Eq0.24 EarningsApr 25 BMO Payout96.30% Avg Volume2.81M Price76.24
Recom2.00 SMA203.07% SMA502.50% SMA2003.58% Volume3,570,731 Change2.18%
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Mar-07-17Downgrade Exane BNP Paribas Neutral → Underperform
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Nov-10-16Upgrade Argus Hold → Buy
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Sep-20-16Initiated Chardan Capital Markets Buy $95
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Apr-25-17 04:45PM  Novartis Earnings Top, But Sales Dip Despite New Blockbuster Drug Investor's Business Daily
03:46PM  Novartis, Amgen Divvy Global Marketing of New Migraine Drug
01:53PM  Novartis Tops Q1 Earnings: Cosentyx, Entresto Boost Sales Zacks
12:01PM  Novartis to speed up bid for MS drug approval, changes target Reuters
11:39AM  Novartis sets sights on return to growth in 2018 Reuters
09:09AM  GlaxoSmithKlines 1Q17 Estimates: Revenues Expected to Grow Market Realist
08:28AM  Stock Futures See More Gains on a Stream of Positive Earnings
08:22AM  Will Low Pricing for Siliq Be Enough to Help Valeant Turn Things Around? Motley Fool
06:00AM  Novartis beats 1Q profit forecasts Associated Press
05:56AM  Swiss drugs giant Novartis posts 15 percent drop in profit Associated Press
05:56AM  Novartis Shares Jump After Group Holds To Full Year Forecasts; Sees Entresto Growth
02:59AM  [$$] Novartis Profit Dented by Investment in New Drugs The Wall Street Journal
01:26AM  Novartis Moves M&A Search to Early-Stage Drugs on Price Gain Bloomberg
Apr-24-17 04:18PM  Biotech And Pharma Industry And Stock News Investor's Business Daily
04:14PM  How Lilly's New Drug Could Spark A Deeper Rivalry With Pfizer, Novartis Investor's Business Daily
10:37AM  Analyst Ratings and Recommendations for Novartis Market Realist
07:38AM  Novartiss 1Q17 Estimates for Sandoz Market Realist
05:52AM  Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS Zacks
12:02AM  Novartis Tests New Alzheimers Drug on People Who Dont Have the Disease The Wall Street Journal
Apr-23-17 06:15PM  Novartis Tests New Alzheimer's Drugs on People Who Don't Have the Disease The Wall Street Journal
11:41AM  Should Gilead Sciences Be Worried About Allergan? Motley Fool
Apr-21-17 04:35PM  Novartiss 1Q17 Estimates: Innovative Medicines Segment Market Realist
03:05PM  Analysts Expect Novartiss Revenues to Remain Flat in 1Q17 Market Realist
01:13PM  Analyst Estimates for Novartiss 1Q17 Earnings Market Realist
12:25PM  Three Hot Junior Biotech Plays Investopedia
07:12AM  Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL Zacks
Apr-20-17 01:40PM  An Alcon Sale Will Take a Bargain Price Bloomberg
10:19AM  Novartis (NVS) Q1 Earnings: Will the Stock Disappoint? Zacks
Apr-19-17 11:47AM  Novartis AG : NVS-US: Dividend Analysis : March 03rd, 2017 (record date) : By the numbers : April 19, 2017 Capital Cube
10:11AM  Allergan (AGN) Collaborates with Novartis to Treat NASH Zacks
10:01AM  Novartis' (NVS) CTL109 BLA Gets Breakthrough Therapy Status Zacks
Apr-18-17 04:36PM  Could Lilly Outperform These Bigger Rivals On Strong Diabetes Meds? Investor's Business Daily
12:22PM  Why the Ionis Spinoff Will Be a Win for Long-Term Investors Motley Fool
07:09AM  Novartis Predicts Chinese Drug Market Growth Will Accelerate Bloomberg
07:05AM  Novartis Snags Coveted FDA 'Breakthrough' Label for CAR-T, Trial Results Still Under Wraps
05:51AM  Novartis CEO Says Trump Discussed Pricing With Drug CEOs Bloomberg Video
05:37AM  Novartis CEO Says Pharma Needs to Step Up Its Efforts Bloomberg Video
04:07AM  Novartis advances with push on cancer and liver disease Reuters
03:09AM  Novartis (NVS) Up 7.7% Since Earnings Report: Can It Continue? Zacks
Apr-17-17 05:56PM  10 Most Profitable Companies In Europe Insider Monkey
01:11PM  Jerome Dodson Buys 2 Stocks, Sells 2 in 1st Quarter
Apr-13-17 04:21PM  Here's Why the Best Is Yet to Come for Ionis Pharmaceuticals, Inc. Motley Fool
Apr-11-17 09:17AM  Forget Novartis, Buy These Two Pharma Stocks Instead Zacks
Apr-09-17 07:22AM  5 Pharmaceutical Stocks With the Most Reliable Dividends Motley Fool
Apr-08-17 09:43AM  Why Juno Therapeutics Stock Slumped in March Motley Fool
07:22AM  3 Big Pharma Companies With the Best Pipelines Motley Fool
Apr-07-17 05:03PM  Novartis (NVS) In-Licenses Ophthalmic Drug from Lubris LLC Zacks
01:38PM  Analysts Release New Health Care Stock Ratings
Apr-06-17 10:20PM  Tiny Mass. biotech strikes licensing deal with Novartis worth up to $1B American City Business Journals
04:20PM  The First CAR-T Drugs Have Left the Gate Motley Fool
08:22AM  Novartis Licenses ECF843 Eye Drops From Lubris Investopedia
Apr-05-17 12:36PM  Cowen Downgrades Novartis, Strengths 'Now Balance Its Risks' Benzinga
12:20PM  Novartis Keeps 'JULIET' Study Results Close as Investors and Rival Kite Pharma Wait
Apr-04-17 03:22PM  Novartis' Tafinlar, Mekinist Get EU Approval for NSCLC Zacks
09:06AM  Could SEG101 Revolutionize the Treatment for Sickle Cell Disease? Market Realist
09:06AM  Targeted Research and Development May Boost Novartiss Profits Market Realist
07:36AM  Could Novartiss CTL019 Capture Significant Market Share? Market Realist
07:36AM  Novartis Expects to Restore Alcons Profitability in the Future Market Realist
07:24AM  Questioning Ionis Pharmaceuticals' Spinoff Announcement Motley Fool
Apr-03-17 10:39AM  What Have Clinical Trials of Novartiss LEE011 Demonstrated? Market Realist
10:39AM  Novartis Aims to Turn Around Its Surgical Business in 2017
09:07AM  Whats the Status of Novartiss Investigational Breast Cancer Drug?
09:06AM  Novartis Expects to Witness Flat Revenue Growth in 2017
09:05AM  Does Novartis See Much Potential for Its Surgical Business?
07:37AM  Investigational Breast Cancer Drug Could Boost Novartiss Position
07:36AM  Novartis Is Focused on Creating Shareholder Value in 2017
07:35AM  Will Novartiss Alcon Business See Growth in 2017?
04:32AM  Novartis' Lung Cancer Drug Combo Gets EU Nod at Investopedia
Apr-02-17 12:18PM  [$$] At Glaxo, a New CEO Steps In, Must Wring More From R&D at The Wall Street Journal
Apr-01-17 12:08AM  [$$] Glaxos New CEO Is a Steady Hand in Pharmaceuticals Rolling Seas at The Wall Street Journal
Mar-31-17 03:35PM  How Novartis Has Improved Operational Efficiencies in R&D Program
03:32PM  3 Attractive Healthy Dividend-Paying Market Gems at Forbes
02:05PM  Consistent Performance Measurement May Improve Novartiss R&D
12:21PM  Will Trump's FDA Chill Innovation Or Kill 'Astronomical' Prices?
12:19PM  Novartis Focuses on Portfolio Prioritization to Boost Profitability
10:36AM  Novartis Expects to Launch 5 Key Biosimilars by 2020
10:35AM  Entresto Could See Strong Uptake in European Markets in 2017
09:06AM  Novartis Has Revamped Its Commercial Strategy for 2017
09:05AM  Entresto Could See Steep Rise in Total Prescriptions This Year
07:37AM  Novartis Has Developed a Robust Innovation Strategy
07:36AM  How Novartis Is Aiming to Increase Entresto Sales in 2017
07:21AM  Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?
Mar-30-17 05:05PM  Changing Demographics Offer Novartis a Strong Growth Opportunity
03:13PM  Why Have Novartiss Valuation Multiples Fallen?
10:50AM  Novartis' CTL109 BLA Gets Priority Review Status from FDA
10:50AM  Novartis' CTL109 BLA Gets Priority Review Status from FDA at Investopedia
10:36AM  Reduced Co-pays May Boost Demand for Entresto
09:08AM  Novartis' Leukemia Drug Secures Priority Review at Investopedia
09:06AM  What Could Boost Medicare Demand for Novartiss Entresto?
07:36AM  Why Entresto Could Become Key Growth Driver for Novartis in 2017
07:36AM  Performance of GlaxoSmithKlines Vaccines Business in 2016
01:36AM  Novartis says U.S. regulator grants speedy review of CAR-T cell therapy Reuters
Mar-29-17 06:15PM  Novartis Makes Plans For Its Cancer-Killing T Cells at Forbes
02:04PM  Mylan stock sinks 2% after FDA fails to approve its generic asthma medication at MarketWatch
10:36AM  Cosentyx Enjoys Solid Demand as Psoriasis Therapy in Europe
09:06AM  Which Segments Will Drive the Most Growth for Novartiss Cosentyx?
07:37AM  Novartiss Cosentyx Managed to Achieve Blockbuster Status in 2016
Mar-28-17 08:45PM  Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen
06:05PM  Will Novartis See Rise in Net Profit Margins in 2017?
04:35PM  Why Novartis Could Witness Modest Revenue Growth in 2017
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Innovative Medicines, Sandoz, and Alcon. The Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. It franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies. The Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The Alcon segment offers eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses for use in surgical procedures to treat cataracts, vitreoretinal conditions, glaucoma, and refractive errors; and contact lenses and lens care products. The company has collaboration and licensing agreements with Xencor for the development of bispecific antibodies for treating cancer; and with Surface Oncology to access four pre-clinical programs in immuno-oncology. It also has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and Caribou Biosciences for the development of drug discovery tools. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerMar 15Buy5.00560,0002,800,0005,805,550Mar 17 08:36 PM
Novartis Bioventures Ltd10% OwnerOct 31Buy13.0084,6151,099,9952,545,652Oct 31 04:50 PM
Novartis Bioventures Ltd10% OwnerOct 31Sale13.003394,40762,575Oct 31 04:50 PM
Novartis Institutes for BioMed10% OwnerMay 11Buy18.00277,7774,999,9865,573,658May 11 06:57 PM